Description
OVA-conjugated hyaluronic acid is characterized by its stability and targeted delivery capabilities, making it a promising candidate for immunomodulation and vaccine development studies. It is formulated in PBS (pH 7.4) containing 0.01% SKL, 1mM DTT, 5% trehalose, and Proclin300.
